FY2025 EPS Estimates for Scholar Rock Lowered by Analyst

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities researchers at HC Wainwright cut their FY2025 EPS estimates for shares of Scholar Rock in a report released on Tuesday, September 23rd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($3.66) for the year, down from their previous estimate of ($3.63). HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($3.51) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.13) EPS and FY2029 earnings at ($0.18) EPS.

Several other research firms also recently commented on SRRK. Leerink Partners began coverage on shares of Scholar Rock in a research note on Monday, September 15th. They issued an “outperform” rating and a $51.00 price target for the company. Cantor Fitzgerald began coverage on shares of Scholar Rock in a research report on Thursday, July 17th. They set an “overweight” rating for the company. Raymond James Financial set a $53.00 price objective on shares of Scholar Rock and gave the stock a “strong-buy” rating in a research report on Wednesday, July 30th. Wedbush reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, June 18th. Finally, Barclays decreased their price objective on shares of Scholar Rock from $45.00 to $44.00 and set an “overweight” rating for the company in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating and ten have given a Buy rating to the company’s stock. According to data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and a consensus target price of $46.40.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $33.72 on Thursday. The company has a fifty day simple moving average of $34.33 and a two-hundred day simple moving average of $33.06. The company has a market cap of $3.24 billion, a price-to-earnings ratio of -11.59 and a beta of 0.36. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.21. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same period last year, the business posted ($0.60) EPS.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Scholar Rock by 2.1% in the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company’s stock valued at $155,773,000 after acquiring an additional 101,723 shares during the last quarter. Bellevue Group AG raised its holdings in shares of Scholar Rock by 17.6% in the second quarter. Bellevue Group AG now owns 2,947,295 shares of the company’s stock valued at $104,393,000 after buying an additional 440,405 shares during the last quarter. Eventide Asset Management LLC raised its holdings in shares of Scholar Rock by 9.5% in the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after buying an additional 251,638 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Scholar Rock by 26.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,018,000 shares of the company’s stock valued at $64,879,000 after buying an additional 423,131 shares during the last quarter. Finally, Hood River Capital Management LLC raised its holdings in shares of Scholar Rock by 1.6% in the second quarter. Hood River Capital Management LLC now owns 1,974,964 shares of the company’s stock valued at $69,953,000 after buying an additional 30,806 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total value of $32,725.18. Following the completion of the sale, the director directly owned 33,914 shares of the company’s stock, valued at $1,103,222.42. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mo Qatanani sold 3,353 shares of the business’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $30.67, for a total transaction of $102,836.51. Following the completion of the sale, the insider directly owned 108,964 shares of the company’s stock, valued at approximately $3,341,925.88. This trade represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,739 shares of company stock valued at $1,516,584 over the last ninety days. Insiders own 13.30% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.